







































































































































































whereas BTV‐related clinical disease  is mostly  reported  in sheep. However, also cattle and 
other ruminants can develop clinical disease, but at a lower frequency, as reported during the 
Northern European BTV‐8 epidemic during  the years 2006  to 2009. BTV  is a haemorrhagic 
fever,  thus,  the  clinical  signs  are mostly  related  to  vascular  injuries.  Affected  animals  can 
develop fever, ulcers and erosions, lameness and coronitis, weakness and depression, as well 










with  the  invasion of  several different serotypes  in Europe,  the need  for a  fast and reliable 
diagnostic tool for molecular ‘serotyping’, including the differentiation between classical and 
atypical  BTV,  led  to  the  development  of  the  optimized  diagnosis  tool  “BlueTYPE  array”. 
Moreover, monitoring of a BTV‐25‐positive goat flock in Bavaria allowed detailed research on 

















1.2‐0.8  kbp  (Seg  7‐10).  Each  of  the  ten  BTV  segments  has  identical  conserved  terminal 
sequences  at  the  5’  –NTRs  (5′‐GUUAAA)  and  3′  NTRs  ((A/G)CUUAC‐3′)  with  only  a  few 
exceptions [3]. The segments 1 to 8 have each one ORF coding for one viral protein, whereas 
the segments 9 and 10 have one large and one small ORF and therefore encode two proteins. 




associated  to  12  decamers  and  encloses  the  10  viral  genome  segments  as  well  as  the 
transcriptase complex consisting of a VP1 monomer (1302 aa; polymerase), a VP4 dimer (644 




to  the hexameric  rings  (in  Latin  “orbi”  for  ring) of  the VP7  (349 aa)  capsomeres  visible by 
electron  microscopy,  once  the  icosahedral  symmetric  outer  capsid  layer  is  removed. 
Subsequently,  the core particle of BTV comprises  the sub‐core particle with  the VP7  layer. 
Finally, the outer capsid layer of BTV is formed by 120 VP5 trimers (526 aa) serving as underlay 































second small ORF of segment 9  [5] and  is an  interferon antagonist downregulating several 
























avoid  the  host  cell  defence  activated  by  direct  contact with  dsRNA  [26].  For  initial mRNA 
synthesis, BTV carries the transcriptome complex formed by VP1, VP4 and VP6 into the host 
cell [1]. The removal of VP2 and VP5 activates the transcriptase complex and the ten genomic 
segments  are  transcribed  into  single  stranded  mRNAs  [12].  VP4  is  capping  the  mRNA 















protein,  mediating  virus  release  by  membrane  permeabilization.  Thus,  the  assembled 
particles can leave the host cell by lysis. On the other hand, NS3 can bind to the Tsg101 cellular 
protein  (human  tumour‐susceptibility  gene  101),  which  facilitates  virus  release  by  vesicle 




vertebrate  blood  (see  figure  3).  After  replication  in  the  arthropod  vector,  arboviruses  are 









The  transmission  cycle  of  BTV  starts with  the  blood meal  of  the  female Culicoides 
midges  on  the  viraemic  ruminant  host  [37].  C.  variipennis  females  are  able  to  ingest 
approximately 0.1 to 1 µl blood [38]. When the BTV positive blood is incorporated, the blood 
meal enters the mid‐gut diverticulum and for 1‐2 days, nearly no virus  is detectable  in the 































Environmental  conditions  such  as  seasonality  and  meteorology  influence  the 
occurrence  of  Culicoides,  and  consequently  determine  Bluetongue  virus  spread  [46].  A 
warmer climate  increases  the vector competence of  the poikilothermic Culicoides  in many 
ways e.g with higher biting and virus replication rates, shorter extrinsic incubation times, but 
also modified mortality  rates  of midges  [41,  47].  The minimum  temperature  required  for 






late  summer  or  autumn  [46].  In  Germany  during  the  years  2006  to  2008  the  Culicoides 









inter‐seasonal  overwintering  [53,  54].  Furthermore,  the  transplacental  transmission might 












by  intake  of  infectious  colostrum,  and  other  cattle  due  to  ingestion  of  BTV‐contaminated 
placentas [58, 59]. In addition, saliva‐ or blood‐contaminated feed or water was proposed to 
infect cattle with BTV‐8 and BTV‐1 during experiments [56, 60]. 
Alternative  biological  vectors  like  ticks  are  in  discussion  [61]  as  well  as  alternative 
mechanical vectors like Melophagus ovinus [62]. BTV can be also transmitted iatrogenically 
e.g. by the use of shared needles [63]. Besides, infected rams and bulls occasionally shed the 
virus  in  the  semen  together  with  blood  cells.  Consequently,  during  viremia  venereal 










40°N and 35°S of  the world.  First mentioned  in 1876  in  sheep  in  South Africa as  ‘Malarial 
catarrhal fever’ or ‘Bekziekte’ (Africaans for moth‐sickness), the first outbreaks of Bluetongue 





non‐filterable  virus  [65,  66].  Furthermore,  Theiler  developed  the  first  live  attenuated  BTV 
vaccine by serial passaging and in South Africa between 1907 and 1943 more than 50 million 
vaccine  doses were  used  [66‐68].  In  1943,  the  usage  of  this  first monovalent  vaccine was 
stopped, due to insufficiencies in immunity [69, 70]. In the 1940’s, evidence for the existence 
of different serotypes was provided linked to the optimised growth of BTV in embryonated 





neutralisation  assays  with more  or  less  observed  cross  reactions  between  serotypes.  The 
virus/serum  neutralization  test  (V/SNT)  has  become  the  reference  method  for  serotype 
identification. With the rapid progress  in genomics  in recent decades, more and more BTV 
sequence  data  have  become  available.  The  segment‐2/VP2  sequence  identities  correlate 
perfectly with  the  respective BTV serotype  [71, 72],  and  in 2011, an  international working 











However,  it  has  to  be  considered  that  a  high  genetic  diversity  has  been  described 
among BTV strains even within the same serotype. One reason of the high diversity rate  is 
most  likely genetic  shift occurring by  reassortment of one or more  segments  in  the  insect 
vector or mammalian host cells (see figure 5) but also the general properties of RNA viruses 
with their error‐prone polymerase, with short generation times and high progeny. Genetic 














































the  episystem  in  Southern  parts  of  Europe  (Mediterranean  Basin),  where  C.  Imicola 






analysed  the  route  from  Morocco‐Algeria  to  Spain  and  showed  a  high  correspondence 
between the model results and the real bluetongue introduction and spread in southern Spain 
[85]. The anthropogenic  is an  important  factor  for  the worldwide spread of BTV. With  the 
international  trade between e.g.  Europe  and Africa,  infected  animals were moved  to  new 
regions. Moreover, the use of live attenuated vaccines in endemic countries like South Africa 











In  Europe,  before  1998  BTV  appeared  only  sporadically.  However,  in  Cyprus  BTV 
occurred regularly before the 1990s and is historically considered as BTV endemic zone [41]. 
Since  1998  the  BTV  situation  in  Europe  changed  radically with  the  presence  of Culicoides 



























by  trade  restrictions and costs of  control measures  including mass vaccination, one of  the 
biggest cost factors [95]. The origin of the European BTV‐8 strain might have been a modified 























illegal  use  of  live‐attenuated  vaccines might  have  introduced  BTV‐6  into  Netherlands  and 
Germany. Interestingly, BTV‐6 disappeared from Europe without any further control measures 
[101, 102].  In Belgium, BTV‐11 was  isolated  from cattle  [103], but only  limited spread was 





In  August  2015,  a  French  clinical  diseased  ram  was  tested  positive  for  BTV‐8  and 
marked the start of the first BTV‐8 re‐emergence in Europe after 2006 [105]. At the time point 
of re‐emergence, the French cattle population was estimated to be ≥ 80% naive with only 18% 
BTV‐8  pre‐immune  cattle  [106].  BTV‐8  could  have  continued  to  spread  subclinically  in 
domestic or wild ruminants before the re‐emergence in 2015 [106]. However, comprehensive 
phylogenetic analyses revealed too high sequence identities between the BTV‐8 isolates from 
2015  and  older  BTV‐8  isolates  from  2007.  With  only  seven  mutations  in  difference,  the 
expected evolutionary  changes of  the BTV‐8 genome during a 5‐year  subclinical  spreading 
period were  absent. Most  likely,  the  second  BTV‐8  endemic was  caused  by  an  accidental 
release  e.g.  through  BTV‐8  contaminated  frozen material  like  bull  semen.  An  unlikely  and 
implausible  alternative  for  the  second  outbreak  could  have  been  an  undetected  ongoing 
persistent infection without high level viral replication for several years [107]. Nevertheless, 
the few observed mutations in the new BTV‐8‐genome led to a less virulent re‐emerged BTV‐
8  strain with  reduced  pathogenicity  [108].  Unfortunately,  only  a  limited  amount  of  BTV‐8 
vaccines was available  in 2015/16  from vaccine producers, and  together with high vaccine 
costs, it was problematic to eradicate BTV‐8. Since 2018, due to the increased case numbers 
in  France,  the  whole  country  was  declared  enzootic  for  both  BTV‐4  and  BTV‐8  [89]. 
Furthermore, BTV‐8 was firstly reported again  in Germany (2018),  in Switzerland (2019),  in 
Luxembourg (2019), and in Belgium (2019) [107, 109, 110]. In Germany, the first case of BTV‐


















whereas RNA  is much  longer detectable  for up  to 222 dpi  [113]. Duration of  viremia after 
experimental  infection  in  small  ruminants  lasted  about  34  to  37  days  without  significant 






and  llamas was  shorter  compared  to  cattle, which  is  in  line with  the  reduced BTV binding 













disease,  even  fatal  [120,  123].  Likewise,  pronghorn  antelope  (Antilocapra  americana), 
American bison (Bison bison), and African buffalo (Syncerus caffer) show sometimes clinical 
disease  [120,  124]. On  the other hand,  no  clinical  signs were  reported  for  the  susceptible 
blesbock (Damaliscus pygargus)  [125] and the mountain gazelle (Gazella gazelle)    [120], as 
well  as  the  North  American  elk  as  close  relative  to  the  European  red  deer  [120,  126]. 
Bluetongue outbreaks in domestic animals appeared to be more or less correlating with the 
prevalence  of  BTV  in wild  ruminants,  suggesting  that  wild  ruminants might  play  a  role  in 
bluetongue epidemiology [127]. In Europe, the red deer population is the most relevant wild 




















Bluetongue  disease  can  cause  a  highly  variable  disease  outcome  depending  on  a 







signs  than cattle, which can be explained by  the different  susceptibly of bovine and ovine 
endothelial cells [138, 139]. Furthermore, the ratio of thromboxane to prostacyclin is higher 
in  BTV‐infected  sheep  and  thromboxane  is  a  great  inducer  of  microvascular  injury  and 
thrombosis [12, 138, 140]. Indeed, the virulence of different strains in sheep is correlating with 
the severity of vascular lesions they induce and with the serum concentrations of acute phase 
proteins, but not directly with viral  loads [141]. BTV circulation  is  linked to the  life span of 
blood cells, because BTV is highly‐cell associated. Platelets are short‐lived, but the longer life 
span  of  erythrocytes  leads  to  a  prolonged  viremia  in  the  blood  and  enables  even  the  co‐






BTV  can  also  replicate  in  the  skin  itself  [142].  Peripheral mononuclear  blood  cells  are  the 
secondary sites of replication, but also the endothelium, peri‐endothelial cells, pericytes of 
capillaries, small arterioles and venules particularly of the lung and the spleen [70, 140]. With 
ongoing  replication, BTV  spreads with  the blood and  lymph  stream  through  the body and 













the  small  blood vessels  in  the oral  cavity  leads  to erosions and ulcers of  the oral mucosa, 
whereas  affected  blood  vessels  in  the  coronet  lead  to  coronitis  and  lameness.  Serous  to 
bloody  nasal  discharge  with  crusts  around  the  nares  and  muzzle  can  be  seen.  Vascular 
thrombosis  and  infarcts  occur  also  in  the  upper  gastrointestinal  tract,  subcutis,  heart  and 
skeletal  muscle  as  well.  Oedema  of  the  head,  neck,  lungs  and  thoracic  cavity,  as  well  as 





severe  pulmonary  oedema,  whereas  pleural,  pericardial  and  abdominal  effusions  are 
apparently not as characteristic of severe BT in cattle as in sheep [94, 140, 143]. For several 





















genetically  very  closely  related  re‐emerged  BTV‐8  strain  in  2015,  showed  a  reduced 
pathogenicity compared to the BTV‐8 strain during 2006‐2009 [108]. Nevertheless, in a high 





The  innate  immune  system  is  important  to  enhance  the  adaptive  immune  response.  The 
adaptive immune system can protect the animal from BTV disease, either cellular mediated 
by T cells and also mediated by antibodies [12].  
The  innate  immune  response  is  the  hosts’  first  line  defence  after  BTV  enters  the 
animals’ skin through the bite of a Culicoides midge. Dendritic cells, recruited in a high number, 
quickly  transport  the  virus  into  the  regional  lymph  node.  The  initial  replication  occurs  in 
dendritic  cells,  macrophages,  endothelium  and  lymphocytes  [141,  151].  Then,  the  virus 
disseminates further in the body to secondary replication sites [112, 121, 141]. The different 






The  virus‐induced  cytokine  and  chemokine  mediators  limit  and  control  the  infection  and 
promote  the  development  of  a  strong  immune  response.  As  a  consequence,  the  cytokine 





of  virus‐infected  cells.  The  cell‐mediated  immunity  in  ruminants  is  poorly  characterized, 




[152,  153].  Interestingly,  when  the  CD8+  cytotoxic  T  lymphocytes  from  a  previously  BTV 










and  serological  surveys  are  usually  targeting  the  VP7  protein  due  to  the  cross‐serotype 
reactivity [153, 160, 161]. The neutralizing epitopes of BTV are located on the VP2, which is a 



















BTV spread  for eradication and safe animal movements  [95, 163]. Other control  strategies 
directed against the vector population like repellents can be very challenging and insufficient 
particularly  for  extensively  kept  livestock  [160,  168]. Nevertheless,  protection  afforded  by 




The  first MLV vaccine used  in South Africa  from 1907  to 1943 was  the monovalent 
Theiler’s strain [64, 66, 69]. Nowadays, the used MLV vaccines in South Africa are polyvalent 
and  each  of  the  three  formulations  contains  five  different  BTV  serotypes  [168,  170‐172]. 
Methods for attenuation of life BTV are alternate passaging in cell culture and embryonated 
chicken  eggs  [168].  The MLV  vaccines  are  effective  in  local  animal  populations  or  in  early 
stages of  recent outbreaks  to minimise BTV circulation  [173]. Consequently, MLV vaccines 
have been applied in endemic countries like South Africa, Italy, Bulgaria, Israel, France, India, 
Turkey and Spain [168, 174]. The great advantages of MLV are the cheap and easy production 




during viremia for  infecting vectors  [173, 175, 176]. Overall,  the safety of BTV‐MLV can be 













methods  using  hydroxylamine  or  binary  ethylenimine  [168,  179,  181‐183].  Inactivated 
vaccines contain the killed virus mixed with an adjuvant, which stimulates non‐specifically the 
immune response. In the last years, mono‐ and multivalent vaccines were developed for BTV‐
1,  ‐2,  ‐4,  ‐8, and ‐9 [168]. The big advantage of  inactivated BTV‐vaccines  is  their very good 




vaccination  campaigns  with  inactivated  vaccine  was  to  reach  at  least  80  %  coverage  of 
domestic  ruminants  [164,  178].  Disadvantages  of  the  inactivated  vaccines  are  the  higher 
production  costs  and  the  requirement  of  booster  immunizations  [95].  Nevertheless, 
inactivated vaccines can be also highly efficient [95], and some studies even revealed a six‐
year antibody longevity of BTV‐8 group‐ and serotype‐specific neutralising antibodies, as well 





of  immunogenic BTV proteins, or  immunogenic proteins  themselves as subunits  [168, 186, 
187].  Recombinant  vector  vaccines  induce  a  strong  neutralizing  immunity  and  have  the 
potential for a “single dose immunity”. Several different non‐pathogenic viruses were used as 








(VLP)  are  produced  by  infecting  insect  cells  with  genetically modified  baculovirus  vectors 
expressing several BTV virus proteins [168]. These proteins assemble to so‐called “empty viral 
particles” and mimic the immunogenic structure of native BTV [168]. Multiple doses of the 
VLP  mixed  with  adjuvants  might  be  necessary,  but  the  vaccine  is  stable,  highly  safe  and 
efficient [168, 189]. Unfortunately, the biggest disadvantage of all these novel vaccine types 
are the high production costs compared with MLV or inactivated vaccines, because they are 
more  difficult  to  design  and  produce.  Consequently,  none  of  these  novel  vaccines  is 
commercially available up to now [168].  
2.9. Diagnostics of bluetongue virus 
BTV  infection  is  followed  by  viremia  in  the  blood  and  can  be  detected  by  virus  isolation 
through embryonated chicken eggs (ECE), by cell culture or less commonly by inoculation of 
sheep.  BTV  can  also  be  detected  by  antigen  ELISAs  and  the  viral  RNA  by  diverse  RT‐PCR 
methods from an extracted blood or tissue sample. The time window of BTV RNA detection is 
with 111‐222 dpi quite prolonged comparing to the actual viremia lasting less than ≤9 weeks 
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of  the most  sensitive  isolation methods  is  the  inoculation  of  9‐12  days  old  embryonated 
chicken eggs (ECE) by using the  intravascular  (IV)  inoculation route [191]. Highest recovery 
rates  are  reported  by  isolation  in  ECE  followed  by  passages  in  cell  culture  for  further 
replication. For virus isolation in cell culture several mammalian and insect derived cell lines 
are  in  usage.  Interestingly,  the  insect‐derived  cell  lines  do  not  show  necessarily  CpE 
(Cytopathic Effect), but in mammalian cells CpE is normally prominent. Commonly used cell 
lines are  the  insect derived Culicoides  sonorensis cell  line  (KC),  the Aedes albopictus clone 
C6/36 cell line and for mammalian cell lines the baby hamster kidney cells (BHK‐21), a clone 




















Primers  for  RT‐qPCRs  for  typing  the  serotypes  1,  2,  4,  and  9,  as  well  as  approaches  for 
differentiation  of  field  and  vaccine  strains  in  Europe were  e.g.  published  by  the  Pirbright 
Institute (TPI) in 2004 [14],and in an expanded version for BTV‐1, ‐2, ‐4, ‐8, ‐9, and ‐16 in 2007 

















detecting  serotype‐specific  antibodies  and  of  particularly  interest  in  endemic  regions with 
more than one BTV serotype circulating. For an SNT the test serum is incubated together with 
the reference virus strains, whereas for a VNT the test virus strain is incubated with the BTV 









are  the  “atypical”  or  “small  ruminant”  BTV  [210,  211].  The  atypical  BTV  were  numbered 












BTV‐25  (Toggenburg Virus—TOV) was detected  in  two different asymptomatic goat 
flocks in the Toggenburg region in Switzerland [219]. Similarly to the naturally infected goats, 
experimentally  TOV‐infected  goats  did  not  develop  any  clinical  signs  typical  for  BTV,  even 
though they exhibited a high virus replication rate [215, 220]. Experimentally TOV‐infected 



































to  be  further  analysed  [223].  Nasal  or  ocular  secretion,  as  well  as  oral  transmission  or 
mechanically  by  infected  blood  via  small  injuries  cannot  be  excluded  [226].  [211]. 







seems  to  be  rare  [229,  230].  The  origin  for  the  spatial  dissemination  of  the  three  BTV‐27 
variants are unknown, but sera from BTV‐27v01‐infected goats did not neutralize BTV‐27v02 







only  proven experimentally  for  BTV‐27/FRA2014/v02. Most  of  the  experimentally  infected 









sharing  high  sequence  similarities,  which  might  indicate  a  common  ancestor,  whereas 
segment 9 resembles to BTV‐Y TUN2017 (Tunisian atypical strain detected in 2017) suggesting 
reassortment  [214].  The  experimental  infection  in  ewes  with  BTV‐28/1537/14  showed 
moderate clinical disease including fever, conjunctivitis, inflammation of gums, coronitis and 
tongue cyanosis. BTV‐28 is pathogenic and might be also transmitted directly as control goats 


















than  vector‐borne.  BTV‐X‐ITL2015  might  have  been  introduced  to  Sardinia  by  import  of 
affected goats [210].  
















One  of  the most  important  tools  in  BTV  control  and  eradication  is  vaccination.  In 
Europe  during  the  first  BTV‐8  epidemic  from  2006‐2009  huge  vaccination  campaigns with 





Several different  serotypes  invaded Europe and  serotype  specific  vaccination  is  the 
major control measure. Our novel developed diagnostic tool “BlueTYPE” RT‐qPCR array can 
be used for the swift identification of outbreak serotype(s), but also in daily laboratory work 
for  excluding  cross  contaminations  e.g.  in  cell  culture  propagated  viruses.  Therefore,  the 
developed “BlueTYPE” array contains RT‐qPCRs for all classical serotypes condensed in one 
array format and enables fast and reliable molecular ‘serotyping’. Furthermore, by including 











































































































5.1. Longevity of vaccine derived antibodies and the effect on vaccination and 
surveillance programs 
For the control and eradication of the BTV-8 epidemic from 2006-2009 in Europe, 
compulsory large-scale vaccination campaigns were implemented using different inactivated 
BTV-8 vaccines [95, 98, 164]. The commercially available, inactivated whole-virus vaccines 
were tested to be safe in application and efficient in protective immunity in short [233] and 
long term studies [233, 234]. Presence of neutralizing antibodies post BTV-8 vaccination was 
shown for up to 6 years in cattle [184] and 7.5 years in sheep [185]. However, further data are 
necessary e.g. for a better understanding of the duration of seropositivity following BTV 
vaccination. From 2009 until the end of our study, no new BTV infection was reported in 
Germany. We analysed 157 cattle born after 2009 with a recorded BTV-8 vaccination history 
to ensure the vaccine origin of circulating BTV-8 antibodies. Thus, we were able to analyse the 
longevity of vaccine-derived group- and serotype specific antibodies of cattle during a time 
span of 5 to 8 years post BTV-8 vaccination with a variable number of re-vaccinations. 
Therefore, we grouped the cattle in groups 5 to 8, representing the approximated time spans 
of 5 to 8 years between the last BTV vaccinations and the sampling time points. With the VP7-
specific cELISA we could determine group-specific, and with the SNT serotype specific 
antibodies. 
In our study, the cELISA showed a specificity of 100%, whereas several of the SNT 
positive samples were tested negative in cELISA. This is in line with previous studies [235]. The 
two methods target two different types of antibodies, directed towards VP7 in the case of the 
cELISA and VP2 in the case of the SNT. The group-specific antibodies directed against VP7 can 
only neutralize the BTV core particles, but not the intact virus particle. 
Our study revealed the presence of neutralising BTV-8 antibodies in more than 50 % of 
the analysed cattle (n= 14) 8 years post BTV-8 vaccination. Since the presence of neutralising 
antibodies strongly correlates with protection of the animals [235], this is also an indication of 
a long term protection of those animals against BTV-8 infection. Thus, a large part of BTV-8 
vaccinated cattle might have acquired protection against BTV-8 infection that lasts at least 8 
years. However, the level of neutralising antibodies does not always correlate with protection 




[154, 163, 236]. Nevertheless, the long-term benefit of BTV-8 inactivated vaccines in cattle is 
remarkable and should be considered in vaccination and prevention campaigns particularly as 
BTV-8 has been able to re-emerge in Northern Europe [105]. In comparison, the protection 
period of vaccines for other disease can be quite a bit shorter, like for Influenza A, where 
conventional vaccines are only effective for a short period of time and even uncertain from 
year-to-year [237]. For inactivated FMD vaccines protection periods of 4 to 12 months were 
reported and revaccinations at regular intervals of six months are necessary to sustain 
protective immunity [238]. For African Swine Fever still no vaccine is available [239]. 
In all four groups 5, 6, 7 and 8, we found seroprevalences in both the cELISA and the 
SNT of ≥50 % independently of the number of vaccinations received. Thus, even after only a 
basic immunisation against BTV-8 (one initial application and one subsequent booster), cattle 
can develop a long-lasting humoral response to BTV-8 (see Paper I). However, the number of 
booster vaccinations significantly increased the percentage of seropositive cattle to up to 90% 
with already one revaccination. For the long-term perspective of controlling the spread of 
BTV-8 and eradicating the disease, the FAO recommended 5 years of vaccination of 95% of 
susceptible cattle and sheep [240]. Nevertheless, the cost-benefit calculations are the critical 
point particularly for livestock owners to decide whether to vaccinate their livestock or not, 
but also for the choice of surveillance strategies [241]. The vaccine costs per dosage alone was 
calculated with 0.40 Euro and cattle require two doses for primary immunisation [242]. The 
benefit of vaccination can reduce the economic impact of treatment and production losses 
particularly in dairy cattle [243]. Nevertheless, on the basis of our data, the yearly re-
vaccination scheme recommended by the manufacturer should be revisited, as it might 
further limit the acceptance of vaccination by livestock owners. Our data might positively 
influence the acceptance of BTV vaccination among the farmers by showing that a reduction 
of necessary booster vaccinations is possible. 
We observed less than 20 % of “none” or “poor responders” despite BTV-8 vaccination. 
Faulty entries of BTV vaccination in the HIT database cannot be excluded, however, there are 
several factors which influence the success of vaccination outcome (see Paper I). Thus, the 
choice of the vaccine itself can increase the success of vaccination, as it was shown for 
BTVPUR® AlSap 8 (Merial, France) in contrast to Zulvac® 8 Bovis (Zoetis, Belgium). The 
difference of the two vaccines might be explained by its intrinsic qualities like the 




Bovis) or the composition of adjuvants and excipients [244]. Furthermore, animals vaccinated 
by a trained veterinarian had a 2-fold higher probability to seroconvert than those vaccinated 
by untrained veterinarians [244]. Moreover, young animals had a 5-fold higher probability to 
seroconvert in comparison to older animals, because the immune response is stronger in 
younger animals [244]. In addition, animals boosted with a heterologous vaccine had higher 
neutralizing antibody titers than those boosted with the vaccine already used for primary 
immunization [236]. Finally, an important factor for the success of BTV-vaccination might be 
the genetic background of the host, as potential single nucleotide polymorphism (SNPs) and 
toll like receptors (TLRs) were connected with disease resistance and humoral and cell-
mediated immune response [245].  
Overall, vaccination with inactivated BTV-8 vaccines proved to be a highly effective tool 
in BTV-8 control. Furthermore, high safety was proven for all commercially available vaccines 
and the protection period of the inactivated BTV-8 vaccines is remarkably long in comparison 
to e.g. vaccines for Influenza A or FMD. These findings might positively influence the 
acceptance of BTV vaccination by showing that a reduction of necessary booster vaccinations 
is possible, despite the yearly revaccination schedule recommended by the producers.  
5.2. The “BlueTYPE array” as novel diagnostic tool for high-performance BTV serotyping 
Real-time (RT)-PCR ((RT)-qPCR) based on TaqMan technology has become the most 
common qPCR technique [193], and numerous RT-PCR assays for the identification of BTV 
serotypes and strains have been developed over time. Fast serotype identification, as well as 
the detection of eventually multiple serotypes in one sample are important for efficient 
disease control, but also for a well-controlled laboratory work. Serotype identification up to 
now can be performed mainly by running numerous single serotype-specific RT-PCRs or by 
serological assays. Therefore, we developed a novel low-density RT-qPCR array named 
“BlueTYPE”, which comprises a single well combination of 29 TaqMan-real-time-RT-PCR assays 
for the identification of all known 24 classical BTV serotypes in only one PCR run (see Paper 
II). The advantage is that BlueTYPE identifies single or multiple serotypes present in a BTV 
positive sample within a single PCR run. Furthermore, when PCR plates are pre-filled with the 
primer-probe mixes and stored at−20 °C, the handling of BlueTYPE becomes very simple. Thus, 
after adding the extracted RNA, results are achieved in less than 2 hours. Moreover, we 
equipped the BlueTYPE array with an extraction control by adding a beta-actin assay in a 




A similar system was recently reported for the typing of influenza A viruses [248]. For result 
interpretation, the different pan-BTV and serotype-specific RT-qPCR systems can be analysed 
not only qualitatively, but also semi-quantitatively regarding the viral genome loads, which 
could be very helpful or even essential for plausibility checks. Altogether, these features of 
the BlueTYPE array increase the reliability of diagnostic test results immensely.  
In detail, we integrated the OIE-listed Pan-BTV-S10-RT-qPCR as broad-range control 
assay (detecting all classical and atypical BTV serotypes) into the BlueTYPE array to generally 
confirm the presence of BTV genomes in the PCR template. The Pan-BTV-S10-RT-qPCR detects 
all currently circulating BTV serotypes including the atypical BTV strains. This is of high 
importance since the number of discovered atypical BTV strains is increasing worldwide. 
However, atypical BTV have a very different status and are not notifiable in the EU. Hence, the 
newly developed Pan-BTV-S1-RT-qPCR assay of this study is of great interest for BTV 
diagnostics, as it can differentiate between classical and atypical BTV strains. It is an adaption 
of the assays already published by Toussaint et al. in 2007 [247], and was mainly modified 
based on the BTV segment 1 sequence data of the classical BTV serotypes 1–24 published in 
the last years. By integration of the novel Pan-BTV-S1-RT-qPCR assay into the BlueTYPE array, 
we ensure that a BTV positive sample is first analysed specifically for the presence of classical 
BTV strains. A negative result in the Pan-BTV-S1-RT-qPCR combined with a positive result in 
the Pan-BTV-S10-RT-qPCR subsequently suggests the presence of an atypical BTV strain in the 
sample of interest. Then, serotype specific RT-qPCRs for the existing atypical BTV strains as 
well as partial or complete sequencing of segment 2 is used to characterize the putative 
atypical BTV strain.  
However, if no serotype could be identified in a valid BlueTYPE array run, 
mutations/variations of the segment 2 genome may not be covered by the oligo’s selected for 
the respective classical serotypes. In this case, alternative strategies can be used for 
serotype/strain identification like partial or complete sequencing of the VP2 gene or even 
whole genome sequencing. Nevertheless, the here developed BlueTYPE array is the first-
choice diagnostic tool for analysing BTV positive sample, as sequencing methods are much 
more labour and cost intensive. 
The high flexibility and simplicity of the BlueTYPE array is of remarkable importance 
regarding the genetic variability of BTV, particularly the serotype-defining segment 2. Both 




genome [70]. However, necessary changes of single BTV assays within the array due to novel 
sequence information can easily be integrated by adding a new or adapted primer/probe 
combination. In order to ensure a high sensitivity and specificity, we based the array on the 
serotype-specific TaqMan assays developed by the Pirbright institute  in 2016, since those 
assays were broadly tested with a representative Orbivirus reference collection [127] [74]. For 
developing novel RT-qPCR assays with high sensitivity and specificity as well as for keeping the 
RT-qPCR assays for BTV detection up to date, it is of utmost importance to publicly share all 
available Bluetongue and Orbivirus virus sequences. In addition to previously validated PCRs, 
several RT-qPCR assays developed in this thesis were integrated into BlueTYPE to further 
improve the diagnostic performance of molecular BTV-serotyping. In the case of novel strains 
or serotypes, the array panel can easily be extended. Furthermore, relevant non-BTV real-time 
RT-PCR assays can be also integrated in the array format. Thus, the concept of BlueTYPE is of 
particular value in countries dealing with diseases of differential-diagnostic importance like 
FMD and PPR [249]. In addition, the identification of mixed infections like with PPRV in sheep 
can easily be realized [250]. In conclusion, thanks to its flexible design, the BlueTYPE array is a 
state-of-the art diagnostic tool suitable for use in different epidemic situations and adaptable 
in the future. 
5.3. The atypical Bluetongue virus serotype 25 
Several novel “atypical” Bluetongue virus (BTV) serotypes were discovered in mostly 
clinically healthy small ruminants worldwide. In 2018, we detected BTV-25 genomes by RT-
qPCR in connection with an export investigation in two goats from a holding in southern 
Germany. After experimental inoculation of two goats with BTV-25 positive blood samples, 
viremia could be ascertained in one goat. And for the first time, a BTV-25-related virus could 
isolated in cell culture from the fresh EDTA blood of the infected goat and a full genome of 
the unique isolate “BTV-25-GER2018” could be generated. Interestingly, strain BTV-25-
GER2018 was only incompletely neutralized by ELISA-positive sera. Fortunately, we could 
further monitor the affected goat flock of approximately 120 goats over several years. The 
EDTA blood samples were screened with RT-qPCRs and serum samples were tested using a 
commercial BTV cELISA. Overall, the presence of BTV-25-GER2018 was detected over 4.5 years 
in the affected goat flock with intermittent PCR-positivity in some animals, and with or without 




This study allowed for the first time a detailed long-term view on the occurrence of 
BTV-25, and it was for the first time possible to propagate a BTV-25-related strain in cell 
culture. However, it remains unclear why BTV-25-GER2018 could grow in cell culture in 
contrast to the closely related two other BTV-25 strains TOV [215] and BTV-Z ITL2017 [212]. 
BTV-25-GER2018 was propagated on BSR cells, which is in line with previous reports that BSR 
cells support a productive BTV infection with a clear CpE [251]. However, future studies should 
target, whether BTV-25-GER2018 is able to replicate in insect cell lines like in KC or C6/36 cells, 
as this was not part of the current study. BTV-26 could only be propagated in mammalian cells, 
suggesting that BTV-26 might be unable to initiate infection in KC cells. With reverse genetics 
the segments Seg-1/VP1, Seg-2/VP2, Seg-3/VP3 and Seg-7/VP7 were identified to possibly 
play a role in the inability of BTV-26 to replicate in KC cells [213]. However, TOV and BTV-Z 
ITL2017 failed to be propagated in both, mammalian cell lines and insect-derived cells [212, 
215]. Similar studies with the different BTV-25 strains could reveal genome segments 
restricting the growth of both BTV-Z ITL2017 and TOV in cell culture and should be a major 
aim in future studies. Nevertheless, differences in the handling and isolation procedure 
between the different laboratories cannot be excluded to play a role either. It has been known 
for a long time, that the conserved terminal ends of BTV play a role in virus replication [252]. 
However, only a ‘serotyped’ TOV strain has been available for in vitro studies so far, where 
the ORFs of the TOV genome segments were inserted into a BTV-1 backbone [221]. Hence, 
the NTR of TOV was that of a classical viral strain. Only this recombinant BTV-TOV virus has 
been available for VNTs until now. Our BTV-25 isolate for the first time enables in vitro and in 
vivo studies with a ‘100%’ representative BTV-25 genome. 
Furthermore, we have robust evidence for persistent BTV-25 infection based on the 
goat flock monitoring over several years. The lack of neutralising antibodies is a further hint 
for persistent infections. Unfortunately, we can only suspect a 4.5-year persistence, because 
further consecutive yearly samples were not available for our study. In general, Orbiviruses 
are not known for causing persistent infection [140]. However, persistent infection of γδ T 
cells was suggested as overwintering strategy for Bluetongue virus [55]. But no other working 
group could reproduce the results of Takamtsu et al, and the current opinion is therefore that 
BTV infection might be prolonged but not persistent. Interestingly, for Middle Point Orbivirus 
(MPVO) another species of Orbiviruses, an apparent persistent infection in naturally infected 




reported for TOV-infected goat flocks [222], the possible persistence mechanisms of atypical 
BTV infections should be further investigated. 
Interestingly, goats in the BTV-25-GER2018-positive goat flock, showed variable 
genome loads independently of their antibody level. The renewed positive virus detections of 
several goats during the surveillance period could be also interpreted as re-infections. On the 
other hand, the virus might persist in the goats without permanent viremia, and a kind of 
“inactive carrier goats” might exist. Several animals showed only a weak antibody response 
and low BTV RNA levels during the monitoring period. All these findings are in strong contrast 
to infections with classical BTV strains 1-24. Therefore, also alternative transmission pathways 
should be further studied. 
Atypical BTV strains do not only differ in their biological characteristics, but also 
concerning the genome sequence level. For BTV-25-GER2018, the nt identities for segment 2 
varied from 40.9% (BTV-12) to 60.8% (BTV-10) for the classical serotypes 1–24. On the other 
hand, the identity to the atypical serotypes started from 57.5% with BTV-28/Sheep pox 
vaccine derived BTV to up to 83.4% with TOV. However, the atypical BTV cluster together, 
clearly distinct from the classical BTV strains 1 to 24. Moreover, the atypical BTV strains seem 
to be very well adapted to their small ruminant host by not causing any clinical disease and 
with evidence for persistent infection without viral clearance. Goats can be seen as the natural 
host for atypical BTV, and the atypical BTV strains are perfectly adapted to their host. The 
different pathogenesis and the phylogenetic distance to the classical BTV strains need to be 
considered for further determining the role of atypical BTV strains in Germany, the EU or even 
globally. This raises the question who was first, atypical or classical BTV, and whether they are 
able to reassort despite the molecular discrepancies. 
5.4. Conclusion  
With this thesis, it could be demonstrated that commercially available inactivated BTV-
8 vaccines used for disease control during the large 2006 to 2009 BTV-8 epidemic induced a 
long-lasting antibody response with detectable group specific and serotype specific 
neutralising antibodies for up to 8 years. Furthermore, the booster effect after re-vaccination 
significantly increased the percentage of long-term seropositive cattle; however also the basic 
immunisation (initial immunisation and one booster application) alone led to a high number 




in ongoing serological surveillance studies on one hand, and support on the other hand the 
use of BTV-8 vaccines, as the long-lasting vaccine antibody response might efficiently support 
to remain or regain a BTV-8 free country status after an BTV outbreak.  
While vaccination is one of the most important tools for BTV control and the long-term 
benefit was described in our study for inactivated BTV-8 vaccines, diagnostics is the 
cornerstone for early detection and supports outbreak control and trade. In this thesis, 
molecular serotyping was therefore also a major focus. The newly developed BlueTYPE real-
time RT-PCR array enables both the single or the multiple serotype identification rapidly within 
one PCR run. The BlueTYPE array  is not only a fast-diagnostic tool with easy handling, but also 
highly accurate. As multiple serotypes are circulating currently in Europe, and BTV continues 
to spread, a flexible diagnostic tool as the BlueTYPE array is ideal for samples of the first 
outbreak. Also, in laboratory’s dealing with different BTV strains in cell culture, the BlueTYPE 
array can help to generate monospecific stocks of BTV and to detect possible contaminations. 
Diagnostics and typing of all  24 classical BTV serotypes is crucial for the detection, typing and 
control of notifiable outbreaks. However, there are also so-called atypical BTVs, which are less 
studied, mainly detected in sheep and goats, in most cases avirulent and different to classical 
BTV e.g. concerning host spectrum and immune response. Therefore, the BlueTYPE array is 
equipped for differentiation between the classical BTV serotypes and the atypical BTV strains. 
With this work, we described in addition an atypical BTV strain occurring in Germany 
and were able to monitor a clinically healthy goat flock in southern Germany infected with 
atypical BTV-25 (strain BTV-25-GER2018) over a longer period. The low RNA levels during 
viremia, the fluctuations in antibody titers, the lack of neutralizing antibodies, the observation 
of BTV reinfections and no viral clearance on the flock level suggested very clear differences 
in transmission and pathogenesis in comparison to the classical strains BTV 1 to 24. Most 
importantly, here we describe the first BTV-25 cell culture isolate, which therefore enables 








Bluetongue  virus  (BTV)  is mainly  located  in  regions with  a  tropical  and  subtropical 
climate, however since 1998, several serotypes are endemic in Southern Europe, and since 
the  BTV‐8  incursion  in  2006  also  in  Northern  Europe.  Several  years  after  the  German 




Moreover,  the  basic  immunisation  alone  led  to  a  high  number  of  seropositive  cattle  post 
vaccination. These findings encourage the usage of inactivated BTV‐8 vaccines as a powerful 





distinguish between  typical and atypical BTV strains, which  is necessary, as  the number of 






The  studies  summarized  in  this  thesis  produced major  recent  contributions  to  BTV 
research. We were able to demonstrate the great long‐term benefit of inactivated vaccines 
used for BTV‐8 eradication during the BTV‐8 epidemic in Northern Europe. Furthermore, the 
novel  BlueTYPE  array  extended  BTV  diagnostics  as  a  fast  and  reliable  diagnostic  tool  for 
molecular serotyping and particularly allows the differentiation between classical and atypical 












Das  Blauzungenvirus  (BTV)  kommt  hauptsächlich  in  Regionen  mit  tropischem  und 
subtropischem Klima vor, jedoch sind seit 1998 mehrere Serotypen in Südeuropa und seit den 
BTV‐8  Ausbrüchen  im  Jahr  2006  auch  in  Nordeuropa  endemisch.  Nun,  einige  Jahre  nach 
Beendigung des deutschen BTV‐8  Impfprogramms, standen uns Serumproben von Rindern, 
die vor 5 bis 8 Jahren ihre letzte Impfdosis erhalten hatten, zur Verfügung. Dabei konnten wir 




zur  BTV  Bekämpfung  gezeigt  werden.  Bevor  jedoch  ein  Impfprogram  starten  kann,  ist  es 
entscheidend,  den  BTV‐Serotyp  oder  eventuell  mehrere  an  einem  Ausbruch  beteiligte 
Serotypen  zu  identifizieren.  Dabei  erleichtert  das  im  Rahmen  dieser  Doktorarbeit  neu 
entwickelte Diagnostiktool, der „BlueTYPE Array“, die BTV‐Diagnostik enorm, da er schnell und 
zuverlässig  einzelne  oder  mehrere  Serotypen  innerhalb  nur  eines  PCR‐Laufs  identifiziert. 
Darüber hinaus kann der BlueTYPE Array zwischen klassischen und atypischen BTV‐Stämmen 
unterscheiden,  was  zwingend  erforderlich  ist,  da  die  Anzahl  der  atypischen  BTV‐Stämme 
weltweit  zunimmt.  Diese  meist  avirulenten  BTV‐Stämme  sind  jedoch  nicht 
bekämpfungswürdig. Auch in Deutschland konnten wir vom Auftreten eines atypischen BTV‐




Diese  Arbeit  vereint  somit  wichtige  aktuelle  Beiträge  in  der  BTV‐Forschung.  Wir 
konnten  den  großen  langfristigen  Nutzen  inaktivierter  BTV‐8  Impfstoffe  demonstrieren. 
Darüber  hinaus  erweitert  der  BlueTYPE  Array  die  BTV‐Diagnostik  als  ein  schnelles  und 
zuverlässiges Diagnostikwerkzeug zur molekularen Serotypisierung. Der BlueTYPE Array kann 
zudem  zwischen  klassischen  und  atypischen  BTV‐Stämmen  unterschieden.  Mit  der 
Charakterisierung des deutschen BTV‐25 Strammes, trägt diese Arbeit zum Verständnis der 
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